Psychopathological symptoms during interferon-α and ribavirin treatment: Effects on virologic response [2]

Molecular Psychiatry

Volumn 10, Issue 4, 2005, Pages 332-333

  Maddock, C ^a   Landau, S ^b   Barry, K ^b   Maulayah, P ^b   Hotopf, M ^b   Cleare, A J ^b   Norris, S ^b   Pariante, C M ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; RIBAVIRIN;

ANOREXIA; ANXIETY DISORDER; DEPRESSION; FATIGUE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; LETTER; LIVER BIOPSY; MENTAL DISEASE; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; TREATMENT OUTCOME; VIRUS GENE;

ADULT; ANTIVIRAL AGENTS; ANXIETY; DEPRESSION; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 16844368692     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001634     Document Type: Letter

References (10)

1. Pariante CM et al. Lancet 1999; 354; 131-132.
2. Pariante CM et al. N Engl J Med 2002; 347: 148-149.
3. Maddock C et al. J Psychopharmacol 2004; 18: 41-46.
4. Beck AT et al. Arch Gen Psychiatry 1961; 4: 561-571.
5. Spielberger CD et al. Manual for the State-Trait Anxiety Inventory (Self-Evaluation Questionnaire). Consulting Psychologist Press: Palo Alto, CA, 1970.
6. Chalder T et al. J Psychosom Res 1993; 37: 147-153.
7. Stewart AL, Ware Jr JE. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Duke University Press: Durham, NC, 1992.
8. Capuron L et al. Neuropsychopharmacology 2002; 26: 643-652.
9. Raison CL et al. Brain Behav Immun 2005; 19: 23-27.
10. Loftis JM et al. Neurosci Lett 2004; 365: 87-91.